ClinicalTrials.gg
CompletedNCT05456828Updated Jun 12, 2026

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

A Phase 1/2 interventional study of ASKG712 in Neovascular Age-related Macular Degeneration, sponsored by Visara, Inc.. Completed at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Visara, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
48th of 91
56 · median 62
Started
2023
with 13 others
Phase 1/2
18 of 106
8 open now
Registered
57th of 106
by date

Among the 106 studies in Macular Degeneration with a site in China, this one is the 48th largest by enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 18 in phase 1/2, and was the 57th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

The purpose of the Phase 1/2a study is comprised of single ascending-dose component (Part 1), multiple ascending-dose component (Part 2) and multiple-dose extension component (Part 3) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in patients with neovascular age-related macular degeneration (nAMD).

Read the detailed description

Part 1 of the study is a multicenter, open-label, sequential, single ascending-dose study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in subjects with nAMD.

Part 2 of the study is a multicenter, open-label, sequential, multiple ascending-dose (3 loading doses) study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in subjects with nAMD.

Part 3 of the study is a Phase 2a, multicenter, open-label, randomized, multiple ascending-dose (3 loading doses) expansion study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the 3.0 mg and 6.0 mg doses of ASKG712 in subjects with nAMD.

For Parts 1 and 2, subjects will be sequentially enrolled into different dose-level cohorts following the "3+3" design to determine the maximum tolerated dose (MTD) or the maximum administered dose has been reached. For Part 3 subjects will be randomized 2:1 to the 6.0mg and 3.0mg dose arms.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Signed the form;
  • 2. Male or female subjects with 50\~80 years of age;
  • 3. Active sub-foveal or juxta-foveal choroidal neovascularization (CNV) lesions secondary to neovascular age-related macular degeneration (nAMD);
  • 4. Total lesion area ≤ 12 disc area (DA);
  • 5. BCVA letter score measured at screening of 19\~78 letters.

Exclusion criteria

Exclusion Criteria:

  • 1. History of uveitis in either eye;
  • 2. Current active inflammation or infection in the study eye;
  • 3. Central foveal scar, fibrosis or atrophy of macular in the study eye;
  • 4. Subretinal hemorrhage area in the study eye ≥ 50% of total lesion size;
  • 5. Scar or fibrosis area in study eyes ≥ 50% of total lesion size;
  • 6. History or any concurrent ocular condition which, in the opinion of the investigator, could either confound interpretation of efficacy and safety of ASKG712 or require medical or surgical intervention.
  • 7. Presence of retinal pigment epithelial tear;
  • 8. Previous intraocular operations in the study eye;
  • 9. Uncontrolled previous or current glaucoma in either eye, or previous glaucoma filtering operation in the study eye;
  • 10. Previous anti-VEGF drug treatment within 60 days prior to screening;
  • 11. Diseases that affect intravenous injection and venous blood sampling;
  • 12. Systemic diseases;
  • 13. Any uncontrolled clinical disorders;
  • 14. History of allergy or current allergic response to ASKG712 or fluorescein;
  • 15. Pregnant or nursing women;
  • 16. Subjects should be excluded in the opinion of investigators.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    ASKG712

    Single or multiple ascending dose of ASKG712 by intravitreal injection

    Biological: ASKG712

Interventions

  • BiologicalASKG712

    ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

    Also known as: AM712, VIS-101

06

What researchers measure

Primary outcomes

  1. Incidence of ocular adverse events (AEs) of the study eyes

    Any relevant ocular observations assessed by best corrected visual acuity (BCVA), slit lamp examination, ophthalmoscopy, intraocular pressure, fundus photography, optical coherence tomography (OCT) and angiography

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks

  2. Incidence of non-ocular adverse events (AEs)

    Any changes of clinical safety observations assessed by vital signs, electrocardiograph (ECG), clinical laboratory tests and physical examination

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks

Secondary outcomes

  1. Area under the concentration time curve (AUC)

    To evaluate the systemic pharmacokinetics of ASKG712 in subjects with neovascular age-related macular degeneration (nAMD)

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks

  2. Maximum plasma concentration (Cmax)

    To evaluate the systemic pharmacokinetics of ASKG712 in subjects with neovascular age-related macular degeneration (nAMD)

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks

  3. Anti-Drug Antibody

    To evaluate the immunogenicity of ASKG712 in subjects with neovascular age-related macular degeneration (nAMD)

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks

  4. Mean change from baseline in best corrected visual acuity (BCVA) as measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score

    To evaluate the efficacy of ASKG712 in subjects with neovascular age-related macular degeneration (nAMD)

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks

  5. Mean change from baseline in central subfield thickness (CST) of macula measured by optical coherence tomography (OCT)

    To evaluate the efficacy of ASKG712 in subjects with neovascular age-related macular degeneration (nAMD)

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks

  6. Mean change from baseline in choroidal neovascularization area measured by fundus angiography

    To evaluate the efficacy of ASKG712 in subjects with neovascular age-related macular degeneration (nAMD)

    Time frame: Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No — There is no plan to make IPD or supporting information available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2025, 32 months.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2022
First posted
Jul 13, 2022
StartActual
Feb 10, 2023
Primary completionActual
Nov 3, 2025
CompletionActual
Nov 3, 2025
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05456828
Lead sponsor
Visara, Inc.
Collaborators
Suzhou Aosaikang Biopharmaceutical Co., Ltd., AskGene Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 13, 2022
Start date
Feb 10, 2023
Primary completion
Nov 3, 2025
Completion
Nov 3, 2025
Last update
Jun 12, 2026

Study contacts

Kun Liu, MD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion